logo.jpg
Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program
11 mai 2021 08h00 HE | HalioDx
Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancerExpert clinical centers already involved worldwide in this new Innovation...
logo.jpg
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil
10 déc. 2020 07h45 HE | HalioDx
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil Marseille, France, December 10, 2020 HalioDx SAS, the immuno-oncology...
logo.jpg
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients
03 déc. 2020 07h45 HE | HalioDx
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological...
logo.jpg
New data reinforces Immunoscore clinical utility in localized Colon Cancer
20 oct. 2020 08h00 HE | HalioDx
New data reinforces Immunoscore clinical utility  in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
logo.jpg
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center
09 oct. 2020 08h00 HE | HalioDx
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...
logo.jpg
HalioDx contribution to precision medicine at ESMO 2020
18 sept. 2020 08h10 HE | HalioDx
HalioDx contribution to precision medicine at ESMO 2020 Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of...
logo.jpg
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
10 sept. 2020 07h45 HE | HalioDx
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
logo.jpg
Immunoscore included in ESMO Clinical Practice Guidelines 2020
06 août 2020 07h45 HE | HalioDx
Immunoscore® included in ESMO Clinical Practice Guidelines 2020 Marseille, France, August 06, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been...
logo.jpg
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer
26 mai 2020 07h45 HE | HalioDx
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of...
logo.jpg
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19 mai 2020 07h50 HE | HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s...